After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related, the news flow was fairly light ahead of the Labor Day holiday.
Amarin Corporation plc (NASDAQ: AMRN) took a severe beating after losing a patent appeal related to its synthetic fish oil pill Vascepa. The stock lost over 40% during the week, attributable primarily to the adverse ruling and to a smaller extent to the market sell-off.
Here are the key catalysts for the unfolding week.
- Citi’s 15th Annual BioPharma Conference: Sept. 8-11
- Wells Fargo 2020 Virtual Healthcare Conference: Sept. 9-10
- Baird 2020 Global Healthcare Conference: Sept. 9-10
- BTIG Virtual Biotechnology Conference: Sept. 10-11
- 66th Annual Meeting of the American Rhinologic Society, or ARS, (virtual event): Sept. 10-12
- International Gynecologic Cancer Society, or IGCS, xDigital Annual Global Meeting: Sept. 10-13
- 2020 Psych Congress (virtual event): Sept. 10-13
- MDS Virtual Congress 2020: September 12–16
- MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting: Sept. 11-13
The FDA is set to rule on Mallinckrodt PLC’s (NYSE: MNK) NDA for terlipressin that is being evaluated for treating hepatorenal syndrome type 1. (Saturday)
Applied Genetic Technologies Corp (NASDAQ: AGTC) said it will present an update on its planned Phase 2/3 X-Linked Retinitis Pigmentosa clinical trial design, a re-analysis of dose Groups 2 and 4 data, and new preliminary visual sensitivity data from Group 5. (Wednesday)
MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting Presentations:
Johnson & Johnson’s (NYSE: JNJ) Janssen unit: additional data on the effect of treatment with ponesimod versus teriflunomide on disability measures in patients with relapsing multiple sclerosis.
Roche Holdings AG’s (OTC: RHHBY) Genentech unit: New analyses from the two-year open-label Phase 3b CASTING study of Ocrevus in patients with relapsing-remitting multiple sclerosis, and new data from the SAkura Phase 3 studies of Enspryng in neuromyelitis optica spectrum disorder.
Atara Biotherapeutics Inc (NASDAQ: ATRA): New 12-month data from all four cohorts in the Phase 1a study of ATA188 for the treatment of progressive forms of multiple sclerosis. (Friday)
ARS Meeting Presentations:
VERONA PHARMA P/S ADR (NASDAQ: VRNA) and Ligand Pharmaceuticals Inc. (NASDAQ: LGND): new subgroup analysis from Phase 2b trials with nebulized ensifentrine in chronic obstructive pulmonary disease. (Tuesday)
Lyra Therapeutics Inc (NASDAQ: LYRA): Poster presentation for lead asset LYR-210 for the treatment of chronic rhinosinusitis.
Sutro Biopharma Inc(NASDAQ: STRO): updated data from the Phase 1 study of STRO-002, its FRα-targeting antibody-drug conjugate, in ovarian cancer; The company will hold a conference call Wednesday to discuss the updated data.
MDS Virtual Congress Presentations:
Neurocrine Biosciences, Inc. (NASDAQ: NBIX): new Phase 3 data analyses of Ongentys capsules as an add-on therapy to levodopa/carbidopa in patients with Parkinson’s disease experiencing motor “off” episode and new Phase Ib data of an investigational gene therapy, NBIb-1817 in advanced Parkinson’s disease.
Voyager Therapeutics Inc (NASDAQ: VYGR): 24-month results from the PD-1102 trial evaluating its investigational gene therapy VY-AADC in advanced Parkinson’s disease. (Friday)
Applied Genetic Technologies (Wednesday before the market open)
MEI Pharma Inc (NASDAQ: MEIP) (Wednesday after the close)
IPO Quiet Period Expiry
CureVac BV (NASDAQ: CVAC)
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Source : benzinga.comFollow us: